PE20060075A1 - Composiciones farmaceuticas de alisciren - Google Patents
Composiciones farmaceuticas de aliscirenInfo
- Publication number
- PE20060075A1 PE20060075A1 PE2005000288A PE2005000288A PE20060075A1 PE 20060075 A1 PE20060075 A1 PE 20060075A1 PE 2005000288 A PE2005000288 A PE 2005000288A PE 2005000288 A PE2005000288 A PE 2005000288A PE 20060075 A1 PE20060075 A1 PE 20060075A1
- Authority
- PE
- Peru
- Prior art keywords
- alisciren
- tablet
- resulting
- active ingredient
- granulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMULACION QUE COMPRENDE: A) UN INHIBIDOR DE RENINA TAL COMO ALISCIREN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE EL INGREDIENTE ACTIVO ESTA PRESENTE EN UNA CANTIDAD QUE VARIA ENTRE 46-60% EN PESO; B) UN LLENADOR TAL COMO CELULOSA MICROCRISTALINA; C) AGENTE DE DESINTEGRACION, LUBRICANTE, AGENTE DE DESLIZ, AGLUTINANTE. UN PROCEDIMIENTO DE PREPARACION COMPRENDE: 1) MEZCLAR EL INGREDIENTE ACTIVO Y ADITIVOS Y GRANULAR DICHOS COMPONENTES CON UN LIQUIDO GRANULACION; 2) SECAR UN GRANULADOR RESULTANTE; 3) MEZCLAR EL GRANULADOR SECO CON EXCIPIENTES DE FASE EXTERNA; 4) COMPRIMIR UNA MEZCLA RESULTANTE PARA FORMAR UNA DOSIS ORAL SOLIDA COMO UNA TABLETA DE NUCLEO; 5) OPCIONALMENTE RECUBRIR UNA TABLETA DE NUCLEO RESULTANTE PARA DAR UNA TABLETA CUBIERTA CON PELICULA. DICHA FORMULACION SUPERA LOS PROBLEMAS RELACIONADOS CON LAS PROPIEDADES DEL ALISCIREN. SON UTILES EN EL TRATAMIENTO DE HIPERTENSION, FALLA CARDIACA CONGESTIVA, ANGINA, INFARTO DE PECHO, DOLOR DE CABEZA, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55387804P | 2004-03-17 | 2004-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060075A1 true PE20060075A1 (es) | 2006-03-20 |
Family
ID=34994415
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000288A PE20060075A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de alisciren |
PE2014001265A PE20142101A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
PE2010000272A PE20110121A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001265A PE20142101A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
PE2010000272A PE20110121A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
Country Status (24)
Country | Link |
---|---|
US (3) | US8617595B2 (es) |
EP (2) | EP1729736A2 (es) |
JP (2) | JP2007529456A (es) |
KR (2) | KR101353736B1 (es) |
CN (2) | CN1997354B (es) |
AR (1) | AR048431A1 (es) |
AU (2) | AU2005224010B2 (es) |
BR (1) | BRPI0508833A (es) |
CA (1) | CA2554633C (es) |
EC (1) | ECSP066807A (es) |
ES (1) | ES2747941T3 (es) |
IL (1) | IL177424A0 (es) |
MA (1) | MA28490B1 (es) |
MX (1) | MX347617B (es) |
MY (2) | MY144477A (es) |
NO (1) | NO343217B1 (es) |
NZ (1) | NZ548823A (es) |
PE (3) | PE20060075A1 (es) |
RU (3) | RU2384328C2 (es) |
SG (1) | SG153830A1 (es) |
TN (1) | TNSN06294A1 (es) |
TW (1) | TWI406656B (es) |
WO (1) | WO2005089729A2 (es) |
ZA (1) | ZA200606220B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7232832B2 (en) * | 2002-11-05 | 2007-06-19 | Smithkline Beecham Corporation | Antibacterial agents |
US20070191487A1 (en) * | 2004-03-17 | 2007-08-16 | Rigassi-Dietrich Petra G | Galenic formulations of organic compounds |
TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
GB0605688D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
MX2008012729A (es) * | 2006-04-03 | 2008-10-14 | Novartis Ag | Inhibidores de renina para el tratamiento de hipertension. |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
PE20081157A1 (es) * | 2006-11-07 | 2008-09-26 | Novartis Ag | Forma cristalina de hemifumarato de alisquireno |
MX2009004628A (es) * | 2006-11-09 | 2009-05-15 | Novartis Ag | Sal de alisquireno con acido orotico. |
WO2008098992A1 (en) * | 2007-02-16 | 2008-08-21 | Novartis Ag | Use of organic compounds |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
US20090082458A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched aliskiren |
MX2010003441A (es) * | 2007-09-28 | 2010-04-21 | Novartis Ag | Formulaciones galenicas de alisquireno y valsartan. |
AU2008309059A1 (en) * | 2007-09-28 | 2009-04-09 | Novartis Ag | Pharmaceutical combination of Aliskiren and Valsartan |
RU2483718C2 (ru) * | 2007-09-28 | 2013-06-10 | Новартис Аг | Галеновые композиции алискирена |
JP2011503185A (ja) | 2007-11-13 | 2011-01-27 | テバ ファーマシューティカル インダストリーズ リミティド | ヘミフマル酸アリスキレンの多形形態及びその調製プロセス |
EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
EP2303831A2 (en) * | 2008-06-06 | 2011-04-06 | Teva Pharmaceutical Industries Ltd. | Solid states of aliskiren free base |
EP2143425A1 (de) | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
JP2010031006A (ja) * | 2008-07-17 | 2010-02-12 | Novartis Ag | 有機化合物の使用 |
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
US9026212B2 (en) | 2008-09-23 | 2015-05-05 | Incube Labs, Llc | Energy harvesting mechanism for medical devices |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
EP2189442B1 (en) | 2008-11-20 | 2014-10-01 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
JP2012516299A (ja) | 2009-01-28 | 2012-07-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
EP2216020A1 (en) | 2009-02-05 | 2010-08-11 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
EA201190091A1 (ru) | 2009-02-05 | 2012-01-30 | Крка, Товарна Здравил, Д. Д., Ново Место | Активируемый влагой способ грануляции |
EP2340820A1 (en) | 2009-12-16 | 2011-07-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
AU2010226620A1 (en) | 2009-03-20 | 2011-09-22 | Novartis Ag | Galenical formulations of a fixed dose combination of Valsartan and Aliskiren |
KR20110129482A (ko) * | 2009-03-20 | 2011-12-01 | 노파르티스 아게 | 알리스키렌을 포함하는 제약 조성물 |
JP2010280601A (ja) * | 2009-06-04 | 2010-12-16 | Suntory Holdings Ltd | キシロオリゴ糖高含有錠剤 |
WO2011028919A2 (en) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
EP2382967A1 (de) | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
US20110268797A1 (en) | 2010-04-30 | 2011-11-03 | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi | Multicoated aliskiren formulations |
US20130129791A1 (en) * | 2010-05-04 | 2013-05-23 | Mahmut Bilgic | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof |
HUE051406T2 (hu) | 2012-11-14 | 2021-03-01 | Grace W R & Co | Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók |
CN103099793B (zh) * | 2013-02-06 | 2015-07-15 | 中国人民解放军第二军医大学 | 片剂及其制备方法 |
CN103536576B (zh) * | 2013-10-15 | 2015-07-01 | 海南卫康制药(潜山)有限公司 | 阿利吉仑组合物胶囊 |
RU2545833C1 (ru) * | 2013-12-03 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) | Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3039922A (en) * | 1959-08-17 | 1962-06-19 | Carter Prod Inc | Method of administering tablets having decongestant and anti-histaminic activity |
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
US6264983B1 (en) * | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
EP1312379A4 (en) | 2000-08-25 | 2004-08-25 | Takeda Chemical Industries Ltd | FIBRINOGENIC REDUCTION AGENTS |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
EP1250921A1 (en) * | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
JP2003015880A (ja) * | 2001-06-29 | 2003-01-17 | Toshiba Corp | 携帯情報端末およびアドインプログラム起動方法 |
AU2002363087A1 (en) | 2001-10-18 | 2003-05-06 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
US20030114389A1 (en) * | 2001-11-13 | 2003-06-19 | Webb Randy Lee | Combination of organic compounds |
CA2485081C (en) * | 2002-05-17 | 2013-01-08 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
US20050147629A1 (en) * | 2002-06-28 | 2005-07-07 | Jutta Riedl | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
-
2005
- 2005-03-15 MY MYPI20051084A patent/MY144477A/en unknown
- 2005-03-15 PE PE2005000288A patent/PE20060075A1/es not_active Application Discontinuation
- 2005-03-15 AR ARP050100999A patent/AR048431A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20090494A patent/MY148773A/en unknown
- 2005-03-15 PE PE2014001265A patent/PE20142101A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2010000272A patent/PE20110121A1/es not_active Application Discontinuation
- 2005-03-16 CN CN2005800062331A patent/CN1997354B/zh active Active
- 2005-03-16 SG SG200904140-1A patent/SG153830A1/en unknown
- 2005-03-16 CN CN2013103391479A patent/CN103462913A/zh active Pending
- 2005-03-16 EP EP05716117A patent/EP1729736A2/en not_active Ceased
- 2005-03-16 WO PCT/EP2005/002798 patent/WO2005089729A2/en active Application Filing
- 2005-03-16 CA CA2554633A patent/CA2554633C/en not_active Expired - Fee Related
- 2005-03-16 US US10/590,398 patent/US8617595B2/en active Active
- 2005-03-16 AU AU2005224010A patent/AU2005224010B2/en not_active Ceased
- 2005-03-16 NZ NZ548823A patent/NZ548823A/en not_active IP Right Cessation
- 2005-03-16 EP EP10177494.1A patent/EP2283826B1/en active Active
- 2005-03-16 BR BRPI0508833-0A patent/BRPI0508833A/pt not_active Application Discontinuation
- 2005-03-16 KR KR1020137005111A patent/KR101353736B1/ko active IP Right Grant
- 2005-03-16 KR KR1020067018968A patent/KR101274855B1/ko active IP Right Grant
- 2005-03-16 JP JP2007503280A patent/JP2007529456A/ja not_active Withdrawn
- 2005-03-16 MX MX2012004612A patent/MX347617B/es unknown
- 2005-03-16 TW TW094108055A patent/TWI406656B/zh active
- 2005-03-16 RU RU2006136090/15A patent/RU2384328C2/ru not_active IP Right Cessation
- 2005-03-16 ES ES10177494T patent/ES2747941T3/es active Active
- 2005-04-29 US US11/119,273 patent/US7683054B2/en not_active Expired - Fee Related
- 2005-06-15 US US11/153,728 patent/US8007824B2/en active Active
-
2006
- 2006-07-27 ZA ZA2006/06220A patent/ZA200606220B/en unknown
- 2006-08-10 IL IL177424A patent/IL177424A0/en not_active IP Right Cessation
- 2006-08-30 EC EC2006006807A patent/ECSP066807A/es unknown
- 2006-09-15 TN TNP2006000294A patent/TNSN06294A1/en unknown
- 2006-09-27 MA MA29347A patent/MA28490B1/fr unknown
- 2006-10-16 NO NO20064670A patent/NO343217B1/no not_active IP Right Cessation
-
2009
- 2009-05-26 AU AU2009202069A patent/AU2009202069B2/en not_active Ceased
- 2009-10-20 RU RU2009138446/15A patent/RU2438661C2/ru not_active IP Right Cessation
-
2011
- 2011-08-25 RU RU2011135405/15A patent/RU2480210C1/ru not_active IP Right Cessation
-
2012
- 2012-06-06 JP JP2012129230A patent/JP5925607B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060075A1 (es) | Composiciones farmaceuticas de alisciren | |
CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
PH12015502134B1 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
AR054382A1 (es) | Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
CA2716874A1 (en) | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
BRPI0709847B8 (pt) | composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio | |
PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
EA201171109A1 (ru) | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия | |
MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
GT201300144A (es) | Composiciones farmaceuticas | |
RU2014129508A (ru) | Новая комбинация | |
AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
ES2634020T3 (es) | Formulaciones de compuestos orgánicos | |
CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
PE20120422A1 (es) | Formulaciones orales solidas de (r)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil-7,8-dihidro-6h-pirido-[4,3-d]-pirimidin-5-ona | |
BR0214497A (pt) | Composição farmacêutica que compreende um agonista do receptor 5ht1 | |
AR045719A1 (es) | Formulacion farmaceutica que comprende levotiroxina sodica, celulosa microcristalina y almidon pregelatinizado; uso de la misma para la fabricacion de un medicamento y proceso para preparar dicha formulacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |